APIM Therapeutics is a clinical-stage biotech company focusing on the development of treatments in the fields of oncology and inflammation. It provides a pipeline of peptide drugs that target PCNA-dependent stress responses in cancer cells. The company offers ATX-101, a cell-penetrating peptide regulating cellular responses to stress and in tumor cell evasion from therapy.